share_log

藥明巨諾-B：自願公告 - 與2SEVENTY BIO, INC.達成戰略合作

JW THERAP-B: VOLUNTARY ANNOUNCEMENT - STRATEGIC PARTNERSHIP WITH 2SEVENTY BIO, INC.

香港交易所 ·  Jan 2 07:01
Summary by Moomoo AI
藥明巨諾-B（股份代號：2126）宣布已於2024年1月1日與2seventy bio, Inc.（納斯達克：TSVT）簽訂獨家合作協議，共同在大中華區開發及商業化治療自身免疫性疾病的CAR T細胞療法產品。此戰略聯盟是基於雙方於2022年建立的MAGE-A4項目合作關係之擴展，並將基於藥明巨諾的細胞療法開發能力。合作協議規定，藥明巨諾將負責在中國進行產品的工藝流程開發及首次人體臨床試驗，並與2seventy bio共同分攤費用。藥明巨諾將享有在大中華區開發、生產及商業化產品的獨家許可權，並有資格收取開發、監管及銷售里程碑費用及全球銷售淨額的特許權許可費。藥明巨諾是一家專注於細胞免疫治療產品開發的生物科技公司，而2seventy bio則專注於免疫腫瘤學細胞療法的開發。
藥明巨諾-B（股份代號：2126）宣布已於2024年1月1日與2seventy bio, Inc.（納斯達克：TSVT）簽訂獨家合作協議，共同在大中華區開發及商業化治療自身免疫性疾病的CAR T細胞療法產品。此戰略聯盟是基於雙方於2022年建立的MAGE-A4項目合作關係之擴展，並將基於藥明巨諾的細胞療法開發能力。合作協議規定，藥明巨諾將負責在中國進行產品的工藝流程開發及首次人體臨床試驗，並與2seventy bio共同分攤費用。藥明巨諾將享有在大中華區開發、生產及商業化產品的獨家許可權，並有資格收取開發、監管及銷售里程碑費用及全球銷售淨額的特許權許可費。藥明巨諾是一家專注於細胞免疫治療產品開發的生物科技公司，而2seventy bio則專注於免疫腫瘤學細胞療法的開發。
Pharmaceutical company Jeleno-B (stock code: 2126) announced on January 1, 2024 that it has signed an exclusive cooperation agreement with 2seventy bio, Inc. (Nasdaq: TSVT) to jointly develop and commercialize CAR T cell therapy products for the treatment of autoimmune diseases in Greater China. This strategic alliance builds on the MAGE-A4 project partnership established by the two sides in 2022 and builds on the capacity to develop cell therapies based on the pharmacopoeia. Under the terms of the cooperation agreement, Yao Ming will be responsible for the process development of the product and the first human clinical trial of the product in China, and will share the cost with 2seventy bio. Yao Ming Jeno will have exclusive licenses to develop, produce and commercialize products in Greater China and will be eligible to charge development, regulatory and sales milestone fees and license fees for net global sales. Pharmacyclo is a biotechnology company focused on the development of cellular immunotherapy products, while 2seventy bio focuses on the development of immuno-oncology cell therapies.
Pharmaceutical company Jeleno-B (stock code: 2126) announced on January 1, 2024 that it has signed an exclusive cooperation agreement with 2seventy bio, Inc. (Nasdaq: TSVT) to jointly develop and commercialize CAR T cell therapy products for the treatment of autoimmune diseases in Greater China. This strategic alliance builds on the MAGE-A4 project partnership established by the two sides in 2022 and builds on the capacity to develop cell therapies based on the pharmacopoeia. Under the terms of the cooperation agreement, Yao Ming will be responsible for the process development of the product and the first human clinical trial of the product in China, and will share the cost with 2seventy bio. Yao Ming Jeno will have exclusive licenses to develop, produce and commercialize products in Greater China and will be eligible to charge development, regulatory and sales milestone fees and license fees for net global sales. Pharmacyclo is a biotechnology company focused on the development of cellular immunotherapy products, while 2seventy bio focuses on the development of immuno-oncology cell therapies.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more